+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Incretin-based therapies: review of current clinical trial data



Incretin-based therapies: review of current clinical trial data



American Journal of Medicine 123(3 Suppl.): S28-S37



Incretin hormones are secreted in response to food ingestion and help manage glycemic control by regulating insulin and glucagon release, slowing gastric emptying, and reducing caloric intake. Glucagonlike peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide, secreted from the L-cells of the lower gut and K-cells of the intestines, respectively, are responsible for these incretin effects, which are reduced in patients with type 2 diabetes mellitus. Initially, the rapid degradation of either incretin by dipeptidyl peptidase-4 (DPP-4) complicated the development of viable therapeutics based on either hormone. However, the US Food and Drug Administration (FDA) has approved 2 incretin-based therapies in which their mechanisms of action augment or amplify the effects of naturally occurring GLP-1. Exenatide, a first-in-class GLP-1 receptor agonist, exhibits the same mechanisms of action as native GLP-1. Sitagliptin inhibits the DPP-4 enzyme, thus increasing the half-life of endogenous GLP-1. This review examines data from recent GLP-1 receptor agonist and DPP-4 inhibitor studies in patients with type 2 diabetes, as well as data on other incretin-based therapies in clinical development.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 053810440

Download citation: RISBibTeXText

PMID: 20206729

DOI: 10.1016/j.amjmed.2009.12.007


Related references

Incretin pharmacology: a review of the incretin effect and current incretin-based therapies. Cardiovascular and Hematological Agents in Medicinal Chemistry 10(4): 276-288, 2013

Incretin Pharmacology A Review of the Incretin Effect and Current Incretin-Based Therapies. 2012

Efficacy and safety of incretin based therapies: clinical trial data. Journal of the American Pharmacists Association 49 Suppl 1: S30-S40, 2009

Renal Effects of Incretin-Based Diabetes Therapies: Pre-clinical Predictions and Clinical Trial Outcomes. Current Diabetes Reports 18(5): 28, 2018

Incretin-based therapies in type 2 diabetes: a review of clinical results. Diabetes Research and Clinical Practice 82 Suppl 2: S102-S107, 2008

Distinguishing among incretin-based therapies. Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies. Journal of Family Practice 59(9 Suppl 1): S5-S9, 2010

Incretin-based therapies--review of the physiology, pharmacology and emerging clinical experience. Internal Medicine Journal 41(4): 299-307, 2012

Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies. Journal of Family Practice 59(9 Suppl 1): S20-S27, 2010

Distinguishing among incretin-based therapies. Glucose-lowering effects of incretin-based therapies. Journal of Family Practice 59(9 Suppl 1): S10-S19, 2010

A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe?. Diabetes Care 36(7): 2118-2125, 2014

A Critical Analysis of the Clinical Use of Incretin-Based Therapies Are the GLP-1 Therapies Safe? The benefits by far outweigh the potential risks. 2013

New developments in incretin-based therapies: the current state of the field. Journal of the American Academy of Nurse Practitioners 21 Suppl 1: 631-641, 2014

A Critical Analysis of the Clinical Use of Incretin-Based Therapies Are the GLP-1 Therapies Safe? How safe are the GLP-1-based therapies?. 2013

Incretin-based therapies in prediabetes: Current evidence and future perspectives. World Journal of Diabetes 5(6): 817-834, 2014

Incretin-mimetic therapies and pancreatic disease: a review of observational data. Current Medical Research and Opinion 30(12): 2471-2481, 2015